Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
This study has been designed as a randomized, double-blind, controlled, study to evaluate the
efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg)
versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute
serious or potentially life threatening influenza. Study treatments will be provided for up
to 5 consecutive days.
A Multinational Phase III Study of CS-8958 (MARVEL)
Daiichi Sankyo Co., Ltd.
The primary objective of this study is to confirm the efficacy of CS-8958 administered as a
single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir
phosphate using the time to alleviation of influenza illness. For safety evaluation,
between-group comparisons will be made with regard to incidence of adverse events and other
In a secondary objective, the optimum dosage of CS-8958 for this indication will be evaluated
based on the efficacy and safety of single inhaled low or high dose.
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
Adamas Pharmaceuticals, Inc.
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical
efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus
oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised
adult and pediatric subjects.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.